Effect of etodolac in patients with moderate renal impairment compared with normal subjects

D. Craig Brater, Shirley A. Anderson, Debbie Brown-Cartwright, Robert D. Toto, Andrew Chen, Ginette B. Jacob

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Twenty subjects (10 with normal renal function and 10 with moderate renal insufficiency) participated in an 8-day study to assess the effects of acute and chronic etodolac dosing on renal function. Subjects and patients were hospitalized and followed a controlled diet (150 mEq sodium, 60 to 80 mEq potassium) during the study. A 3-day drug-free period was followed by 4 days of etodolac, 200 mg b.i.d. Sodium balance and body weight remained unchanged in both groups. Modest reductions in renal function as measured by clearances of inulin and p-aminohippurate occurred acutely only in the patients with renal impairment. Chronic therapy resulted in no decrements in daily creatinine clearance. In an average effective anti-inflammatory dose, etodolac did not produce a sustained effect on renal function in either normal subjects or patients with moderate renal insufficiency.

Original languageEnglish (US)
Pages (from-to)674-679
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume38
Issue number6
StatePublished - Dec 1985

Fingerprint

Etodolac
Kidney
Renal Insufficiency
Sodium
p-Aminohippuric Acid
Inulin
Creatinine
Potassium
Anti-Inflammatory Agents
Body Weight
Diet
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Brater, D. C., Anderson, S. A., Brown-Cartwright, D., Toto, R. D., Chen, A., & Jacob, G. B. (1985). Effect of etodolac in patients with moderate renal impairment compared with normal subjects. Clinical Pharmacology and Therapeutics, 38(6), 674-679.

Effect of etodolac in patients with moderate renal impairment compared with normal subjects. / Brater, D. Craig; Anderson, Shirley A.; Brown-Cartwright, Debbie; Toto, Robert D.; Chen, Andrew; Jacob, Ginette B.

In: Clinical Pharmacology and Therapeutics, Vol. 38, No. 6, 12.1985, p. 674-679.

Research output: Contribution to journalArticle

Brater, DC, Anderson, SA, Brown-Cartwright, D, Toto, RD, Chen, A & Jacob, GB 1985, 'Effect of etodolac in patients with moderate renal impairment compared with normal subjects', Clinical Pharmacology and Therapeutics, vol. 38, no. 6, pp. 674-679.
Brater, D. Craig ; Anderson, Shirley A. ; Brown-Cartwright, Debbie ; Toto, Robert D. ; Chen, Andrew ; Jacob, Ginette B. / Effect of etodolac in patients with moderate renal impairment compared with normal subjects. In: Clinical Pharmacology and Therapeutics. 1985 ; Vol. 38, No. 6. pp. 674-679.
@article{fb28e4210eb64aee82635cbd3856d976,
title = "Effect of etodolac in patients with moderate renal impairment compared with normal subjects",
abstract = "Twenty subjects (10 with normal renal function and 10 with moderate renal insufficiency) participated in an 8-day study to assess the effects of acute and chronic etodolac dosing on renal function. Subjects and patients were hospitalized and followed a controlled diet (150 mEq sodium, 60 to 80 mEq potassium) during the study. A 3-day drug-free period was followed by 4 days of etodolac, 200 mg b.i.d. Sodium balance and body weight remained unchanged in both groups. Modest reductions in renal function as measured by clearances of inulin and p-aminohippurate occurred acutely only in the patients with renal impairment. Chronic therapy resulted in no decrements in daily creatinine clearance. In an average effective anti-inflammatory dose, etodolac did not produce a sustained effect on renal function in either normal subjects or patients with moderate renal insufficiency.",
author = "Brater, {D. Craig} and Anderson, {Shirley A.} and Debbie Brown-Cartwright and Toto, {Robert D.} and Andrew Chen and Jacob, {Ginette B.}",
year = "1985",
month = "12",
language = "English (US)",
volume = "38",
pages = "674--679",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Effect of etodolac in patients with moderate renal impairment compared with normal subjects

AU - Brater, D. Craig

AU - Anderson, Shirley A.

AU - Brown-Cartwright, Debbie

AU - Toto, Robert D.

AU - Chen, Andrew

AU - Jacob, Ginette B.

PY - 1985/12

Y1 - 1985/12

N2 - Twenty subjects (10 with normal renal function and 10 with moderate renal insufficiency) participated in an 8-day study to assess the effects of acute and chronic etodolac dosing on renal function. Subjects and patients were hospitalized and followed a controlled diet (150 mEq sodium, 60 to 80 mEq potassium) during the study. A 3-day drug-free period was followed by 4 days of etodolac, 200 mg b.i.d. Sodium balance and body weight remained unchanged in both groups. Modest reductions in renal function as measured by clearances of inulin and p-aminohippurate occurred acutely only in the patients with renal impairment. Chronic therapy resulted in no decrements in daily creatinine clearance. In an average effective anti-inflammatory dose, etodolac did not produce a sustained effect on renal function in either normal subjects or patients with moderate renal insufficiency.

AB - Twenty subjects (10 with normal renal function and 10 with moderate renal insufficiency) participated in an 8-day study to assess the effects of acute and chronic etodolac dosing on renal function. Subjects and patients were hospitalized and followed a controlled diet (150 mEq sodium, 60 to 80 mEq potassium) during the study. A 3-day drug-free period was followed by 4 days of etodolac, 200 mg b.i.d. Sodium balance and body weight remained unchanged in both groups. Modest reductions in renal function as measured by clearances of inulin and p-aminohippurate occurred acutely only in the patients with renal impairment. Chronic therapy resulted in no decrements in daily creatinine clearance. In an average effective anti-inflammatory dose, etodolac did not produce a sustained effect on renal function in either normal subjects or patients with moderate renal insufficiency.

UR - http://www.scopus.com/inward/record.url?scp=0022368198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022368198&partnerID=8YFLogxK

M3 - Article

C2 - 2933206

AN - SCOPUS:0022368198

VL - 38

SP - 674

EP - 679

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -